Kite Pharma (KITE) Tops Q1 EPS by 44c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Kite Reports First Quarter Financial Results
May 8, 2017 8:00 AM EDTCompleted Submission of Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Kites CAR-T Therapy, Axicabtagene Ciloleucel, in Patients with Aggressive Non-Hodgkin Lymphoma (NHL) Initiated Two New Clinical Studies as Part of an Expanded KTE-C19 Development Program Advanced Additional New Cell Therapy Candidates Toward Clinical Study in 2017 Expanded Cell Therapy Account Management Capabilities in Anticipation of Potential Approval and Launch of Axicabtagene Ciloleucel Completed $409.7 Million Follow-On Offering of Common Stock... More
